Q-omics provides the consensus-scored STEAP2 profile across patient tissues and cancer cell-line models. STEAP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STEAP2 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, STEAP2 RNA expression shows 17,621 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where STEAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STEAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STEAP2 survival associations across molecular data types. STEAP2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STEAP2 RNA expression–survival associations across cancer types. High STEAP2 expression shows unfavorable associations in LUAD, GBM and THCA, but favorable associations in KIRC, BRCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STEAP2 RNA expression.
This table summarizes STEAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STEAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STEAP2 shows lower tumor expression in THCA, KIRC, BLCA, UCEC and BRCA and higher tumor expression in LUAD. The THCA box plot shows higher STEAP2 RNA expression in normal versus tumor tissue (log2 FC = −1.892, t-test p < 0.001).
This table shows molecular features associated with STEAP2 in patient tissues and cancer cell lines. In patient samples, STEAP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STEAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
